hVIVO Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 196

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $16.8M

hVIVO General Information

Description

Developer of antiviral drugs and vaccines designed for respiratory and enteric diseases. The company offers testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials.

Contact Information

Website
www.hvivo.com
Formerly Known As
Retroscreen Virology Group, Open Orphan plc, Open Orphan
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Queen Mary BioEnterprises (QMB) Innovation Centre
  • 42 New Road
  • London E1 2AX
  • England, United Kingdom
+44 020
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Armscote Investment Company
Vertical(s)
Life Sciences
Corporate Office
  • Queen Mary BioEnterprises (QMB) Innovation Centre
  • 42 New Road
  • London E1 2AX
  • England, United Kingdom
+44 020

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

hVIVO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 09-Dec-2019 $16.8M Completed Generating Revenue/Not Profitable
6. PIPE 26-Nov-2015 Completed Generating Revenue/Not Profitable
5. PIPE 14-Aug-2014 Completed Generating Revenue/Not Profitable
4. IPO 03-May-2012 Completed Generating Revenue/Not Profitable
3. Later Stage VC 16-May-2011 Completed Generating Revenue/Not Profitable
2. Later Stage VC (Series B) 15-Oct-2009 $4.17M $6.06M Completed Generating Revenue/Not Profitable
1. Later Stage VC (Series A) 24-Aug-2006 $1.89M $1.89M Completed Generating Revenue/Not Profitable
To view hVIVO’s complete valuation and funding history, request access »

hVIVO Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 1
Series B
Ordinary 145,658 $0.001643 $2.93 $2.93 1x $2.93 4.72%
To view hVIVO’s complete cap table history, request access »

hVIVO Patents

  • 46

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

hVIVO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202114655-D0 Biomarkers Inactive 13-Oct-2021
GB-202114656-D0 Biomarker Inactive 13-Oct-2021
GB-201805472-D0 Biomarkers and methods for classifying subjects following viral exposure Inactive 03-Apr-2018
JP-2021507921-A Methods and compounds for the treatment or prevention of hypercytokine storms and severe influenza Active 22-Dec-2017
GB-201721793-D0 Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza Inactive 22-Dec-2017 A61K31/437
To view hVIVO’s complete patent history, request access »

hVIVO Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

hVIVO Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aquarius Equity Partners Venture Capital Minority
Calculus Capital PE/Buyout Majority
IP Group Venture Capital Minority
Northern Initiatives Lender/Debt Provider Minority
Queen Mary University of London Endowment Limited Partner Minority
To view hVIVO’s complete investors history, request access »

hVIVO Investments & Acquisitions (5)

hVIVO’s most recent deal was a Merger/Acquisition with CHIMagents. The deal was made on 15-Jul-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CHIMagents 15-Jul-2020 Merger/Acquisition Other Healthcare Services
Venn Life Sciences 28-Jun-2019 Merger/Acquisition Other Healthcare Services
Imutex 22-Apr-2016 Secondary Transaction - Private Drug Discovery
PrEP Biopharm 02-Nov-2015 Early Stage VC Drug Discovery
Activiomics 04-Mar-2014 Merger/Acquisition Biotechnology
To view hVIVO’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

hVIVO FAQs

  • When was hVIVO founded?

    hVIVO was founded in 1989.

  • Where is hVIVO headquartered?

    hVIVO is headquartered in London, United Kingdom.

  • What is the size of hVIVO?

    hVIVO has 196 total employees.

  • What industry is hVIVO in?

    hVIVO’s primary industry is Biotechnology.

  • Is hVIVO a private or public company?

    hVIVO is a Private company.

  • What is the current valuation of hVIVO?

    The current valuation of hVIVO is .

  • What is hVIVO’s current revenue?

    The current revenue for hVIVO is .

  • How much funding has hVIVO raised over time?

    hVIVO has raised $119M.

  • Who are hVIVO’s investors?

    Aquarius Equity Partners, Calculus Capital, IP Group, Northern Initiatives, and Queen Mary University of London Endowment have invested in hVIVO.

  • When was hVIVO acquired?

    hVIVO was acquired on 09-Dec-2019.

  • Who acquired hVIVO?

    hVIVO was acquired by Venn Life Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »